Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 18 years old~2. Diagnosis of NMO or NMO spectrum disorder~3. Clinical evidence of at least 2 relapses in last 12 months or 3 relapses in the last 24 months~4. Able and willing to give written informed consent and comply with the requirements of the study protocol.~5. EDSS \<= 7.5 (8 in special circumstances)~6. Men and women of reproductive potential must agree to use a highly effective method of birth control from screening to 6 months after final dose of the investigational product.~Exclusion Criteria:~1. Current evidence or known history of clinically significant infection (Herpes simplex virus, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus,human immunodeficiency virus, Hepatitis viruses, Syphilis, etc)~2. Pregnant, breastfeeding, or child-bearing potential during the course of the study~3. Patients will not participate in any other clinical therapeutic study or will not have participated in any other experimental treatment study within 30 days of screening~4. Participation in another interventional trial within the last 3 months~5. Heart or kidney insufficiency~6. Tumor disease currently or within last 5 years~7. Clinically relevant liver, kidney or bone marrow function disorder~8. Intolerance of azathioprine or previous relapses on azathioprine treatment~9. Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior screening and B-cells below the lower limit of normal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): Tocilizumab Injection (ACTEMRA®) , a IL-6 receptor blockade
- Azathioprine (Type: ACTIVE_COMPARATOR): Imuran

Based on this trial design, predict the completion outcome and termination type (if applicable).